News & Updates

Show Multimedia Only

Health supplements: Help or hype?

22 Apr 2026 by

A review of 19 meta-analyses shows mixed results on the effects of multivitamin and mineral (MVM) supplementation on health outcomes.

Health supplements: Help or hype?

22 Apr 2026

Optimizing prostate cancer outcomes with 177Lu-PSMA-617 radioligand therapy

22 Apr 2026 by

Radioligand therapy, which uses prostate-specific membrane antigen (PSMA)–targeted agents to deliver tumour‑focused radiation, has become a key treatment for metastatic castration‑resistant prostate cancer (mCRPC). At an industry‑sponsored meeting, Professor Kim-Nguyen Chi of the University of British Columbia in Vancouver, Canada, discussed how PSMA-targeted radioligand therapy, specifically lutetium 177–PSMA 617 (¹⁷⁷Lu-PSMA-617), is reshaping mCRPC management and optimizes outcomes.

Optimizing prostate cancer outcomes with 177Lu-PSMA-617 radioligand therapy

22 Apr 2026

Two models of palliative care yield similar outcomes in end-stage liver disease

21 Apr 2026

Palliative care delivered by hepatologists yields similar improvements in quality of life (QoL) of patients with end-stage liver disease (ESLD) and is associated with greater patient satisfaction compared with palliative care delivered by specialists, according to a study.

Two models of palliative care yield similar outcomes in end-stage liver disease

21 Apr 2026

Secondary bladder cancer after RT not uncommon in prostate cancer patients

21 Apr 2026 by

A secondary bladder cancer (SBC) rarely occurs among patients with localized prostate cancer who have been treated with radiotherapy (RT), but the incidence rate is not insignificant, reports a study presented at EAU 2026. When it does appear, it usually becomes the primary cause of death in this population.

Secondary bladder cancer after RT not uncommon in prostate cancer patients

21 Apr 2026

Residential radon exposure linked to ovarian cancer

20 Apr 2026

Women residing in homes with high radon levels may be at increased risk of ovarian cancer, as suggested in a study.

Residential radon exposure linked to ovarian cancer

20 Apr 2026

Young adults with glomerular disease at increased risk of cancer

19 Apr 2026

Glomerular disease is associated with an increased risk of cancer, particularly among younger patients who are typically excluded from screening programs, according to a retrospective study.

Young adults with glomerular disease at increased risk of cancer

19 Apr 2026

Cannabis may reduce risk of some skin cancers

18 Apr 2026 by

The use of cannabis appears to result in a lower incidence of basal cell carcinoma (BCC) over 10 years, but not cutaneous squamous cell carcinoma (cSCC) or malignant melanoma (MM), suggests a recent study presented at AAD 2026.

Cannabis may reduce risk of some skin cancers

18 Apr 2026

Head and neck tumours linked to increased mortality in CMM patients

17 Apr 2026

Patients with cutaneous malignant melanoma (CMM) whose tumour is located in the head and neck (HN) are at greater risk of all-cause and cancer-specific mortality than those with tumours found in the trunk, reveals a study.

Head and neck tumours linked to increased mortality in CMM patients

17 Apr 2026

Pegfilgrastim administered 72 h postchemo lessens bone pain

17 Apr 2026

Administrating pegfilgrastim 72 h after chemotherapy, compared with 24- and 48-h administration, results in reduced pegfilgrastim-induced bone pain (PIBP) and does not appear to increase the rates of neutropenia or febrile neutropenia (FN), reports a study.

Pegfilgrastim administered 72 h postchemo lessens bone pain

17 Apr 2026

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

17 Apr 2026

The first-in-class KRAS G12D–targeted protein degrader setidegrasib has demonstrated antitumour activity in patients with previously treated advanced non–small-cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma harbouring the KRAS G12D mutation, according to a phase I study.

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

17 Apr 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

Health supplements: Help or hype?

Health supplements: Help or hype?

Optimizing prostate cancer outcomes with 177Lu-PSMA-617 radioligand therapy

Optimizing prostate cancer outcomes with 177Lu-PSMA-617 radioligand therapy

Two models of palliative care yield similar outcomes in end-stage liver disease

Two models of palliative care yield similar outcomes in end-stage liver disease

Secondary bladder cancer after RT not uncommon in prostate cancer patients

Secondary bladder cancer after RT not uncommon in prostate cancer patients

Residential radon exposure linked to ovarian cancer

Residential radon exposure linked to ovarian cancer

Young adults with glomerular disease at increased risk of cancer

Young adults with glomerular disease at increased risk of cancer

Cannabis may reduce risk of some skin cancers

Cannabis may reduce risk of some skin cancers

Head and neck tumours linked to increased mortality in CMM patients

Head and neck tumours linked to increased mortality in CMM patients

Pegfilgrastim administered 72 h postchemo lessens bone pain

Pegfilgrastim administered 72 h postchemo lessens bone pain

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers

First-in-class KRAS G12D–targeted protein degrader active against lung, pancreatic cancers